Stopping TNF Alpha Inhibitors in Rheumatoid Arthritis

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

290

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

June 30, 2024

Study Completion Date

August 30, 2024

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Etanercept

Subcutaneous

DRUG

Infliximab

Infusion

DRUG

Adalimumab

Subcutaneous

DRUG

Placebo

Matching Placebo

Trial Locations (2)

20007

Georgetown University Medical Center, Washington D.C.

20892

National Institutes of Health Clinical Center, Bethesda

Sponsors
All Listed Sponsors
collaborator

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NIH

collaborator

University of Maryland, Baltimore

OTHER

collaborator

Washington D.C. Veterans Affairs Medical Center

FED

collaborator

Medstar Health Research Institute

OTHER

collaborator

Patient-Centered Outcomes Research Institute

OTHER

collaborator

Arthritis and Pain Associates of PG County

UNKNOWN

collaborator

Arthritis & Rheumatism Associates, P.C.

OTHER

collaborator

Rheumatology Associates of Baltimore, L.L.C.

UNKNOWN

collaborator

The Arthritis Clinic of Northern Virginia, P.C.

UNKNOWN

collaborator

Arthritis and Rheumatic Disease Associates, P.C.

UNKNOWN

lead

Georgetown University

OTHER